IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v538y2016i7626d10.1038_nature19830.html
   My bibliography  Save this article

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Author

Listed:
  • András Kotschy

    (Servier Research Institute of Medicinal Chemistry)

  • Zoltán Szlavik

    (Servier Research Institute of Medicinal Chemistry)

  • James Murray

    (Vernalis (R&D) Ltd.)

  • James Davidson

    (Vernalis (R&D) Ltd.)

  • Ana Leticia Maragno

    (Institut de Recherches Servier Oncology R&D Unit)

  • Gaëtane Le Toumelin-Braizat

    (Institut de Recherches Servier Oncology R&D Unit)

  • Maïa Chanrion

    (Institut de Recherches Servier Oncology R&D Unit)

  • Gemma L. Kelly

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne)

  • Jia-Nan Gong

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne)

  • Donia M. Moujalled

    (Australian Centre for Blood Diseases, Monash University)

  • Alain Bruno

    (Institut de Recherches Servier Oncology R&D Unit)

  • Márton Csekei

    (Servier Research Institute of Medicinal Chemistry)

  • Attila Paczal

    (Servier Research Institute of Medicinal Chemistry)

  • Zoltán B. Szabo

    (Servier Research Institute of Medicinal Chemistry)

  • Szabolcs Sipos

    (Servier Research Institute of Medicinal Chemistry)

  • Gábor Radics

    (Servier Research Institute of Medicinal Chemistry)

  • Agnes Proszenyak

    (Servier Research Institute of Medicinal Chemistry)

  • Balázs Balint

    (Servier Research Institute of Medicinal Chemistry)

  • Levente Ondi

    (Servier Research Institute of Medicinal Chemistry)

  • Gábor Blasko

    (Servier Research Institute of Medicinal Chemistry)

  • Alan Robertson

    (Vernalis (R&D) Ltd.)

  • Allan Surgenor

    (Vernalis (R&D) Ltd.)

  • Pawel Dokurno

    (Vernalis (R&D) Ltd.)

  • Ijen Chen

    (Vernalis (R&D) Ltd.)

  • Natalia Matassova

    (Vernalis (R&D) Ltd.)

  • Julia Smith

    (Vernalis (R&D) Ltd.)

  • Christopher Pedder

    (Vernalis (R&D) Ltd.)

  • Christopher Graham

    (Vernalis (R&D) Ltd.)

  • Aurélie Studeny

    (Institut de Recherches Servier Oncology R&D Unit)

  • Gaëlle Lysiak-Auvity

    (Institut de Recherches Servier Oncology R&D Unit)

  • Anne-Marie Girard

    (Institut de Recherches Servier Oncology R&D Unit)

  • Fabienne Gravé

    (Institut de Recherches Servier Oncology R&D Unit)

  • David Segal

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne)

  • Chris D. Riffkin

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne)

  • Giovanna Pomilio

    (Australian Centre for Blood Diseases, Monash University)

  • Laura C. A. Galbraith

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne)

  • Brandon J. Aubrey

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne
    The Royal Melbourne Hospital, Victorian Comprehensive Cancer Centre)

  • Margs S. Brennan

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne)

  • Marco J. Herold

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne)

  • Catherine Chang

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne)

  • Ghislaine Guasconi

    (Institut de Recherches Servier Oncology R&D Unit)

  • Nicolas Cauquil

    (Institut de Recherches Servier Oncology R&D Unit)

  • Fabien Melchiore

    (Institut de Recherches Servier)

  • Nolwen Guigal-Stephan

    (Institut de Recherches Servier)

  • Brian Lockhart

    (Institut de Recherches Servier)

  • Frédéric Colland

    (Institut de Recherches Servier Oncology R&D Unit)

  • John A. Hickman

    (Institut de Recherches Servier Oncology R&D Unit)

  • Andrew W. Roberts

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne
    The Royal Melbourne Hospital, Victorian Comprehensive Cancer Centre
    Faculty of Medicine, The University of Melbourne)

  • David C. S. Huang

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne)

  • Andrew H. Wei

    (Australian Centre for Blood Diseases, Monash University
    The Alfred Hospital)

  • Andreas Strasser

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne)

  • Guillaume Lessene

    (The Walter and Eliza Hall Institute of Medical Research
    University of Melbourne
    The University of Melbourne)

  • Olivier Geneste

    (Institut de Recherches Servier Oncology R&D Unit)

Abstract

Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.

Suggested Citation

  • András Kotschy & Zoltán Szlavik & James Murray & James Davidson & Ana Leticia Maragno & Gaëtane Le Toumelin-Braizat & Maïa Chanrion & Gemma L. Kelly & Jia-Nan Gong & Donia M. Moujalled & Alain Bruno &, 2016. "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models," Nature, Nature, vol. 538(7626), pages 477-482, October.
    • Handle: RePEc:nat:nature:v:538:y:2016:i:7626:d:10.1038_nature19830
    DOI: 10.1038/nature19830
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature19830
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature19830?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Martina Troiani & Manuel Colucci & Mariantonietta D’Ambrosio & Ilaria Guccini & Emiliano Pasquini & Angelica Varesi & Aurora Valdata & Simone Mosole & Ajinkya Revandkar & Giuseppe Attanasio & Andrea R, 2022. "Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    2. Yexuan Deng & Sarah T. Diepstraten & Margaret A. Potts & Göknur Giner & Stephanie Trezise & Ashley P. Ng & Gerry Healey & Serena R. Kane & Amali Cooray & Kira Behrens & Amy Heidersbach & Andrew J. Kue, 2022. "Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    3. Florian J. Bock & Egor Sedov & Elle Koren & Anna L. Koessinger & Catherine Cloix & Désirée Zerbst & Dimitris Athineos & Jayanthi Anand & Kirsteen J. Campbell & Karen Blyth & Yaron Fuchs & Stephen W. G, 2021. "Apoptotic stress-induced FGF signalling promotes non-cell autonomous resistance to cell death," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    4. Dongwen Lv & Pratik Pal & Xingui Liu & Yannan Jia & Dinesh Thummuri & Peiyi Zhang & Wanyi Hu & Jing Pei & Qi Zhang & Shuo Zhou & Sajid Khan & Xuan Zhang & Nan Hua & Qingping Yang & Sebastian Arango & , 2021. "Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    5. Jessica Ebner & Johannes Schmoellerl & Martin Piontek & Gabriele Manhart & Selina Troester & Bing Z. Carter & Heidi Neubauer & Richard Moriggl & Gergely Szakács & Johannes Zuber & Thomas Köcher & Mich, 2023. "ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    6. Ella N. Hoogenboezem & Shrusti S. Patel & Justin H. Lo & Ashley B. Cavnar & Lauren M. Babb & Nora Francini & Eva F. Gbur & Prarthana Patil & Juan M. Colazo & Danielle L. Michell & Violeta M. Sanchez &, 2024. "Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    7. Jaskaren Kohli & Chen Ge & Eleni Fitsiou & Miriam Doepner & Simone M. Brandenburg & William J. Faller & Todd W. Ridky & Marco Demaria, 2022. "Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    8. Andrea Lopez & Denis E. Reyna & Nadege Gitego & Felix Kopp & Hua Zhou & Miguel A. Miranda-Roman & Lars Ulrik Nordstrøm & Swathi-Rao Narayanagari & Ping Chi & Eduardo Vilar & Aristotelis Tsirigos & Evr, 2022. "Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer," Nature Communications, Nature, vol. 13(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:538:y:2016:i:7626:d:10.1038_nature19830. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.